Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 12:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Crisaborole Clear all
Completed Phase 2 Interventional Results available

Pilot Study Evaluating the Efficacy of a Topical PDE4 Inhibitor for Morphea

NCT03351114
View directory record Official record
Conditions
Morphea
Interventions
Crisaborole
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 31, 2021 · Synced Sep 3, 2026, 12:15 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Long-Term Maintenance Treatment With Once Daily Crisaborole Ointment 2% in Pediatric and Adult Participants With Mild-to-Moderate Atopic Dermatitis

NCT04040192
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Crisaborole 2%, Vehicle
Drug
Lead sponsor
Pfizer
Industry
Eligibility
3 Months and older
Enrollment
620 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
25
States / cities
Fountain Valley, California • Fremont, California • Colorado Springs, Colorado + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2023 · Synced Sep 3, 2026, 12:15 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of AN2728 Topical Ointment to Treat Adolescents With Atopic Dermatitis

NCT01602341
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
AN2728 Topical Ointment, 2% QD, AN2728 Topical Ointment, 0.5% QD, AN2728 Topical Ointment, 2% BID, AN2728 Topical Ointment, 0.5% BID
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years to 17 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
11
States / cities
Fremont, California • Miami, Florida • Lousiville, Kentucky + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2017 · Synced Sep 3, 2026, 12:15 AM EDT
Completed Phase 2 Interventional

Study of Efficacy, Safety and Tolerability of Crisaborole and PF-07038124 With and Without NBUVB in Vitiligo

NCT05298033
View directory record Official record
Conditions
Vitiligo
Interventions
Crisaborole 2 % Topical Ointment, PF-07038124 0.01% topical ointment, NBUVB phototherapy, Sham phototherapy, Vehicle
Drug · Device
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 11, 2024 · Synced Sep 3, 2026, 12:15 AM EDT
Completed Phase 4 Interventional Results available

A Study of Crisaborole Ointment 2% in Children Aged 3-24 Months With Mild to Moderate Atopic Dermatitis

NCT03356977
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Crisaborole ointment 2%
Drug
Lead sponsor
Pfizer
Industry
Eligibility
3 Months to 23 Months
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
23
States / cities
Hot Springs, Arkansas • San Diego, California • San Francisco, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2019 · Synced Sep 3, 2026, 12:15 AM EDT
Withdrawn Phase 2 Interventional

Topical Crisaborole in Patients with Alopecia Areata

NCT04299503
View directory record Official record
Conditions
Alopecia Areata
Interventions
Crisaborole Topical Ointment, Placebo Topical Ointment
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
2 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 27, 2024 · Synced Sep 3, 2026, 12:15 AM EDT
Completed Phase 4 Interventional Results available

A Proof of Concept Clinical Trial Evaluating the Safety and Efficacy of Eucrisa (Crisaborole) in Patients With Seborrheic Dermatitis

NCT03567980
View directory record Official record
Conditions
Seborrheic Dermatitis
Interventions
Crisaborole
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Sep 3, 2026, 12:15 AM EDT
Completed Phase 2 Interventional Results available

Study Evaluating Efficacy and Safety of Crisaborole in Adults With Stasis Dermatitis

NCT04091087
View directory record Official record
Conditions
Stasis Dermatitis
Interventions
crisaborole ointment, vehicle ointment
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
45 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
4
States / cities
El Segundo, California • Lafayette, California • South San Francisco, California + 1 more
Source: ClinicalTrials.gov public record
Updated May 1, 2022 · Synced Sep 3, 2026, 12:15 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Characterizing Skin Microbiome Change in Atopic Dermatitis

NCT04800185
View directory record Official record
Conditions
Atopic Dermatitis, Atopic Dermatitis Eczema
Interventions
Crisaborole 2% Top Oint, Skin Microbiome Swabs
Drug · Genetic
Lead sponsor
University of California, Irvine
Other
Eligibility
2 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Feb 1, 2024 · Synced Sep 3, 2026, 12:15 AM EDT
Completed Phase 4 Interventional

Response of Children With Atopic Dermatitis (Eczema) to Eucrisa

NCT04023084
View directory record Official record
Conditions
Atopic Dermatitis, Eczema
Interventions
Crisaborole
Drug
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
4 Months to 17 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 18, 2022 · Synced Sep 3, 2026, 12:15 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Steroid-reducing Effects of Crisaborole

NCT03832010
View directory record Official record
Conditions
Atopic Dermatitis, Eczema
Interventions
Crisaborole, Hydrocortisone Ointment, Triamcinolone ointment, Aquaphor
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
2 Years to 17 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 18, 2024 · Synced Sep 3, 2026, 12:15 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Wearable Skin Sensors to Assess Nocturnal Scratch Behavior

NCT03770858
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Crisaborole, Scratch sensor
Drug · Device
Lead sponsor
Northwestern University
Other
Eligibility
2 Years and older
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 12, 2023 · Synced Sep 3, 2026, 12:15 AM EDT
Not yet recruiting Phase 4 Interventional

Utilization of a Microdevice for Psoriasis and Atopic Dermatitis

NCT07352566
View directory record Official record
Conditions
Psoriasis, Atopic Dermatitis
Interventions
In situ cutaneous microdevice, Triamcinolone, 5-Fluorouracil, Calcipotriene, Tapinarof, Crisaborole, Tacrolimus, Adalimumab, Etanercept, Certolizumab, Infliximab, Secukinumab, Ixekizumab, Apremilast, Risankizumab, Ustekinumab, Hydroxychloroquine, Methotrexate, Mycophenolate, Azathioprine, Chloroquine, Cyclosporine, Tofacitinib, Deucravacitinib, Dupilumab, Tralokinumab, Guselkumab, Tildrakizumab, Baractinib, Abrocitinib, Upadacitinib, Lebrikizumab, Nemolizumab, Ruxolitinib, Bimekizumab, Roflumilast
Device · Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Sep 3, 2026, 12:15 AM EDT
Terminated Phase 4 Interventional Results available

A Study of Crisaborole Ointment 2%; Crisaborole Vehicle; TCS and TCI in Subjects Aged ≥ 2 Years, With Mild-moderate AD

NCT03539601
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Crisaborole ointment, 2%, Hydrocortisone butyrate cream, 0.1%, Pimecrolimus cream, 1%, Crisaborole Vehicle
Drug
Lead sponsor
Pfizer
Industry
Eligibility
2 Years and older
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
10
States / cities
Bryant, Arkansas • Encinitas, California • Orange Park, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2022 · Synced Sep 3, 2026, 12:15 AM EDT
Completed Phase 2 Interventional Results available

AN2728 Topical Ointment to Treat Mild-to-Moderate Plaque-Type Psoriasis

NCT01300052
View directory record Official record
Conditions
Psoriasis
Interventions
AN2728 ointment, 2%, Ointment Vehicle
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
10
States / cities
New Haven, Connecticut • Louisville, Kentucky • Fridley, Minnesota + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2017 · Synced Sep 3, 2026, 12:15 AM EDT
Completed Phase 3 Interventional Results available

ASPIRE: PROs & Caregiver Burden in Children With Atopic Dermatitis

NCT03645057
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Crisaborole, Tacrolimus 0.03% Ointment
Drug
Lead sponsor
University of Rochester
Other
Eligibility
2 Years to 15 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Oct 30, 2022 · Synced Sep 3, 2026, 12:15 AM EDT
Terminated Phase 4 Interventional Results available

Improvement In Scratch Behavior And Sleep In Patients With Atopic Dermatitis

NCT05200403
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Crisaborole 2%, Vehicle treatment, Accelerometry device for children, Accelerometry device for adult caregivers
Drug · Device
Lead sponsor
Boston University
Other
Eligibility
3 Months to 75 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 13, 2025 · Synced Sep 3, 2026, 12:15 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Ages 2 Years and Older) With Atopic Dermatitis

NCT02118766
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
AN2728 Topical Ointment, 2%, Matching vehicle control
Drug
Lead sponsor
Pfizer
Industry
Eligibility
2 Years and older
Enrollment
763 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Stockbridge, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 5, 2017 · Synced Sep 3, 2026, 12:15 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Aged 2 Years and Older) With Atopic Dermatitis

NCT02118792
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
AN2728 Topical Ointment, 2%, Matching vehicle control
Drug
Lead sponsor
Pfizer
Industry
Eligibility
2 Years and older
Enrollment
764 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Henrico, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 5, 2017 · Synced Sep 3, 2026, 12:15 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety, Tolerability, and PK of AN2728 in Adolescents With Atopic Dermatitis

NCT01652885
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
AN2728 Topical Ointment, 2%
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years to 17 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
6
States / cities
Fremont, California • San Diego, California • Indianapolis, Indiana + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2017 · Synced Sep 3, 2026, 12:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study To Assess Local Tolerability of Crisaborole 2% Ointment and Vehicle Ointment In Healthy Participants Using Subject-reported Assessments and Objective Measurements

NCT03760042
View directory record Official record
Conditions
Healthy
Interventions
Within-Subject Active vs. Placebo Topical Applications
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 23, 2019 · Synced Sep 3, 2026, 12:15 AM EDT
Completed Phase 1 Interventional

Eucrisa for Atopic Dermatitis

NCT03250663
View directory record Official record
Conditions
Mild to Moderate Atopic Dermatitis
Interventions
Online Treatment response, EUCRISA
Behavioral · Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
2 Years to 64 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 1, 2025 · Synced Sep 3, 2026, 12:15 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Improvement of Short Term Outcome of Mild to Moderate Atopic Dermatitis Using a Combination of Crisaborole and a Concomitant Topical Corticosteroid Over a 8 Week Period

NCT04008784
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Crisaborole 2% Topical Application Ointment [EUCRISA], Triamcinolone Acetonide 0.1% Ointment
Drug
Lead sponsor
Clinical Research Center of the Carolinas
Other
Eligibility
2 Years to 79 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 27, 2021 · Synced Sep 3, 2026, 12:15 AM EDT
Not listed Phase 4 Interventional

Study of Crisaborole Ointment 2% in Mild to Moderate Atopic Dermatitis

NCT04214197
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Crisaborole 2% Top Oint
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
2 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 23, 2021 · Synced Sep 3, 2026, 12:15 AM EDT